79173-62-9

Basic information

• Product Name: 3-Methyl-1H-indazol-6-ylamine ,97%
• Synonyms: 3-methyl-1H-indazol-6-amine;1H-Indazol-6-aMine,3-Methyl-;3-Methyl-2H-indazol-6-aMine;CC1=NNC2=C1C=CC(N)=C2;6-AMino-3-Methyl (1H)indazole;6-AMINO-3-MRTHYL(1H)INDAZOLE;3-Methyl-1H-indazol-6-ylamine ,97%;3-Methyl-1H-indazol-6-ylamine
• CAS NO: 79173-62-9
• Molecular Formula: C₈H₉N₃
• Molecular Weight: 147.18
• Mol File: 79173-62-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 376.377 °C at 760 mmHg
• Flash Point: 209.372 °C
• Appearance: /
• Density: 1.295 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.737
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-Methyl-1H-indazol-6-ylamine ,97%(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methyl-1H-indazol-6-ylamine ,97%(79173-62-9)
• EPA Substance Registry System: 3-Methyl-1H-indazol-6-ylamine ,97%(79173-62-9)

Safety Data

• Statements: 22-36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 79173-62-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H9N3/c1-5-7-3-2-6(9)4-8(7)11-10-5/h2-4H,9H2,1H3,(H,10,11)

Upstream product

• 1313372-75-6 3?methyl?6?nitro?1H?indazole 
• 315203-37-3 6-nitro-1H-indazole-3-carboxaldehyde 
• 6494-19-5 3-methyl-6-nitro-1H-indazole 

Downstream Products

• 1089671-52-2 C₂₁H₁₇FN₄O 
• 1122709-91-4 2-chloro-N-(3-methyl-1H-indazol-6-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 201286-99-9 3-methyl-1H-indazol-6-ol 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF PAZOPANIP HCL AND CRYSTALLINE FORMS OF PAZOPANIB HCL

Various crystalline forms of Pazopanib HCl were prepared. In preferred embodiments the obtained Pazopanib HCl is essentially free from CPMI.

PROTEIN KINASE INHIBITORS

Compounds, particularly compounds having spleen tyrosine kinase (Syk) inhibition activity, having the following structure: or a pharmaceutically acceptable salt thereof, wherein R1 is structure (a), (b), (c) or (d): and Ra, Rb, Rc, R2, R3, R4, R5, R6 and R7 are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed, as well as uses of the same to treat a condition or disorder mediated by a Syk and/or JAK kinase.

BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS

The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.